Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Next Previous
Search
Trial Profile

Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IDP 023 (Primary) ; Isatuximab (Primary) ; Cyclophosphamide; Daratumumab; Fludarabine; Interleukin-2; Mesna; Rituximab
  • Indications Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms Indapta-Trial1
  • Sponsors Indapta Therapeutics

    • Most Recent Events

    • 06 Dec 2024 According to an Indapta Therapeutics media release, company has amended its ongoing phase 1 study of IDP-023, to add a cohort of IDP-023 in combination with Sarclisa for patients with relapsed/refractory multiple myeloma.
    • 21 May 2024 According to an Indapta Therapeutics media release, the Cancer Prevention and Research Institute of Texas (CPRIT) has granted the company a competitive product development research award. The fund from $4.5 million grant will be used to treat additional patients in order to reach clinical proof-of-concept in our Phase 1 dose escalation trial Patient enrolled in phase I to date have received up to three planned doses of IDP-023 with or without interleukin-2.
    • 11 Jan 2024 According to an Indapta Therapeutics media release, company also announced that it has successfully manufactured sufficient IDP-023 to supply the Phase 1 clinical trial through the second half of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top